{"created":"2023-05-15T16:31:10.082315+00:00","id":2514,"links":{},"metadata":{"_buckets":{"deposit":"9bf31f63-91ac-4cf3-90b6-93c388dc5435"},"_deposit":{"created_by":2,"id":"2514","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"2514"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00002514","sets":["8:9"]},"author_link":["11728","11729","11733","11726","11724","11730","11723","11727","11731","11725","11732"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017-05-31","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"97","bibliographicPageStart":"92","bibliographicVolumeNumber":"11","bibliographic_titles":[{"bibliographic_title":"The Open Microbiology Journal"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Carbapenems, fluoroquinolones (FQs), and aminoglycosides (AGs) are key drugs for treating Pseudomonas aeruginosa infections, and accumulation of drug resistances make antibiotic therapy difficult.\nMethods: We evaluated 169 patients with imipenem (IPM)-resistant P. aeruginosa and compared patient background and microbiological characteristics between groups with or without FQ resistance. Similar analyses were performed for AG. Results: Of the 169 IPM-resistant strains, 39.1% showed resistance to FQs and 7.1% to AGs. The frequency of exposure to FQs within 90 days previously was higher in the group with FQ resistance (45.5%) than in the group without FQ resistance (13.6%). Similarly, 33.3% of patients in the group with AG resistance had been previously administered AGs, higher than the 7.6% of patients without AG resistance. Frequencies of metallo-β-lactamase (MBL) production were higher in the group with FQ or AG resistance (16.7% or 33.3%) than in the group without FQ or AG resistance (2.9% or 6.4%). Multivariate analyses showed exposures to FQs or AGs were related to the respective resistances. MBL production was a common factor for resistance to FQs or AGs, in addition to IPM-resistant P. aeruginosa. Conclusion: As well as promoting appropriate use of antibiotics, MBL production should be detected as a target of intervention for infection control.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"The Open Microbiology Journal, 11, pp.92-97; 2017","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Bentham Open"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.2174/1874285801711010092","subitem_relation_type_select":"DOI"}}]},"item_2_relation_42":{"attribute_name":"関係URI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"http://hdl.handle.net/10069/38693"}]}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"c 2017 Kosai et al. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited."}]},"item_2_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"18742858","subitem_source_identifier_type":"ISSN"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kosai, Kosuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kaku, Norihito"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Uno, Naoki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Saijo, Tomomi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Morinaga, Yoshitomo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Imamura, Yoshifumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Hasegawa, Hiroo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Miyazaki, Taiga"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Izumikawa, Koichi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Mukae, Hiroshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yanagihara, Katsunori"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-21"}],"displaytype":"detail","filename":"OMJ11_92.pdf","filesize":[{"value":"473.6 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"OMJ11_92.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/2514/files/OMJ11_92.pdf"},"version_id":"d93a7a4e-bc2e-4aa1-aba1-54d457135a97"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Metallo-β-lactamase","subitem_subject_scheme":"Other"},{"subitem_subject":"Drug resistance","subitem_subject_scheme":"Other"},{"subitem_subject":"Infection control","subitem_subject_scheme":"Other"},{"subitem_subject":"Antibiotic therapy","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas aeruginosa","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas aeruginosa"}]},"item_type_id":"2","owner":"2","path":["9"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-08-18"},"publish_date":"2017-08-18","publish_status":"0","recid":"2514","relation_version_is_last":true,"title":["Risk Factors for Acquisition of Fluoroquinolone or Aminoglycoside Resistance in Addition to Carbapenem Resistance in Pseudomonas aeruginosa"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T03:45:16.611710+00:00"}